Completed PHASE2 INTERVENTIONAL 2-arm NCT00428714

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

Phase 2 Trial Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation and (2) After First-Line Cytotoxic Chemotherapy

Sponsor: Eli Lilly and Company

Conditions Prostate Cancer

Interventions enzastaurin

Updated 7 times since 2017 Last updated: Nov 4, 2020 Started: Jan 31, 2007 Primary completion: Jun 30, 2009 Completion: Jan 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00428714, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by Eli Lilly and Company, it has been updated 7 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Dec 2020 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Dec 2020 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Buffalo, United States , Cleveland, United States , Lancaster, United States , Las Vegas, United States , Los Angeles, United States , Madison, United States , Memphis, United States , New Haven, United States , New York, United States and 1 more location